

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal**

**Vorinostat in combination with bortezomib for the treatment of multiple myeloma in people who have received at least one prior therapy**

**Provisional matrix of consultees and commentators (pre-referral)**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Merck Sharp &amp; Dohme (vorinostat)</li> </ul> <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> <li>• Afya Trust</li> <li>• Black Health Agency</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Leukaemia CARE</li> <li>• Leukaemia Society (UK)</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Myeloma UK</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Committee for Standards in</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Aspen Medical Europe (melphalan)</li> <li>• Auden McKenzie (dexamethasone)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Celgene (lenalidomide, thalidomide)</li> <li>• Cephalon UK (doxorubicin)</li> <li>• GlaxoSmithKline (melphalan)</li> <li>• Hameln Pharmaceuticals (doxorubicin)</li> <li>• Hospira UK (dexamethasone, doxorubicin, vincristine)</li> <li>• Janssen (bortezomib)</li> <li>• Medac UK (doxorubicin)</li> <li>• Organon Laboratories (dexamethasone)</li> <li>• Pfizer (cyclophosphamide, doxorubicin)</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of vorinostat in combination with bortezomib for the treatment of multiple myeloma in people who have received at least one prior therapy

Issue date: July 2011

Consultees	Commentators (no right to submit or appeal)
<p>Haematology</p> <ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Myeloma Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• East London &amp; City Alliance</li> <li>• NHS Lewisham</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Rosemont Pharmaceuticals (dexamethasone)</li> <li>• Schering-Plough (doxorubicin)</li> <li>• Teva UK (doxorubicin, vincristine)</li> <li>• Wockhardt UK (doxorubicin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Clinical Trials Research Unit (CTRU), University of Leeds</li> <li>• Cochrane Haematology Malignancies Group</li> <li>• Elimination of Leukaemia Fund</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia and Lymphoma Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.